Mechanisms of hematogenous tumor metastasis.


  • V. I. Desyaterik
  • Y. S. Shevchenko



tumor, cancer, metastasis, thrombosis, platelets


Metastasis is the most common cause of mortality associated with cancer, however, our understanding of these processes is insufficient. Metastasis is the end product of a dynamic process in which different interactions between cancer cells and the microenvironment of the organism result in the changes that allow these cells to exceed programmed behavior. Thus, cancer cells spread to new tissues and, ultimately, cause organ dysfunction and death. Understanding the molecular mechanisms involved in the process of metastasis may help to effectively and purposefully prevent and treat cancer metastasis. Attention of the modern researchers aimed at exploring ways to activate thrombosis, coagulation and formation of blood clots, as a prerequisite for metastasis of tumor cells. Sophisticated mechanisms of inducing and coagulation of platelets in combination with the increased activity of the activating vascular endothelial growth factor provide the onset of metastatic foci at a distance from the primary tumor. Learning and development opportunities to block these mechanisms is a promising way to improve the results of treatment of cancer patients. In this review article, we aimed to provide in a concise manner the prospects of studying mechanisms of tumor metastasis , as well as review existing today additional opportunities to optimize the results of treatment of cancer pathology.


Kahr WH, Lo RW, Li L et al. Abnormal mega-karyocyte development and platelet function in Nbeal2 mice.Blood. 2013;122:3349–58. 2. Barinelli EM. Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and dimi-ni¬shes platelet angiogenic response. Blood. 2014;123:101–12. 3. Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011;17:5858–66. 4. Falanga A, Marchetti M, Vignoli A et al. Clotting me¬cha-nisms and cancer: implications in thrombus forma¬tion and tumor progression. Clin Adv Hematol Oncol. 2003;1:673–8. 5. Kim HK, Song KS, Park YS et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer. 2003;39:184-91. 6. Falanga A, Marchetti M, Vignoli A Coagulation and cancer: biological and clinical aspects. J Thromb Haemost. 2013;11:223–33. 7. Falanga A, Tartari CJ, Marchetti M. Micropar¬tic-les in tumor progression. Thromb Res. 2012;129:132–6. 8. Falanga A, Panova-Noeva M, Russo L. Proco-agulant mechanisms in tumour cells. Best Pract Res Clin Haematol. 2009;22:49-60. 9. Folkman J. Tumor angiogenesis: therapeutic im-pli¬cations. J. Folkman. N Engl J Med. 1971; 285:1182–6. 10. Gao J, Zhang HY, Xia YF [Increased platelet count is an indicator of metastasis in patients with nasopharyngeal carcinoma]. Tumour Biol. 2013;34:39-45. 11. Garnier D, Magnus N, D’Asti E et al. Genetic pathways linking hemostasis and cancer.Thromb Res. 2012;129:22–9. 12. Deppermann C, Cherpokova D, Nurden P et al. Gray platelet syndrome and defective thrombo-inflam-ma¬tion in Nbeal2-deficient mice. Clin Invest. 2013;123:3331–42. 13. Nadir Y, Brenner B, Gingis-Velitski S et al. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. Thromb Haemost. 2008;99:133-41. 14. Coppell JA, Richardson PG, Soiffer R et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16:157–68. 15. Engebraaten O, Trikha M, Juell S et al. Inhibition of in vivo tumor growth by the blocking of host alpha(v)beta3 alphaII(b)beta3 integrins.Anticancer Res. 2009; 29:131-7. 16. Khorana AA Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27:4839–47. 17. Landolfi R, Di Gennaro L, Falanga A. Throm-bosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22:2020–8. 18. Vignoli A, Marchetti M, Russo L et al. LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells. Cancer Investigation. 2011;29:153-61. 19. Medina VA, Histamine ES. [Receptors and cancer pharmacology]. Rivera / Pharmacol. 2010;161:755-67. 20. Fidler IJ. Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2’-deoxyuridine.J Natl Cancer Inst. 1970;45:773-82. 21. Joyce JA, Pollard JW, Muller F, Mutch N, Schenk W et a.l Microenviromental regulation of metastasis. Nat Rev Cancer. 2009;9:239-52. 22. Morowski M, Vogtle T, Kraft P et al. Only severe thrombocytopenia result in bleeding and defective thrombus formation in mice.Blood. 2013;121:4938-47. 23. Klink M, Jastrzembska K, Nowak M et al. Ova-rian cancer cells modulate human blood neutrophils res-ponse to activation in vitro. Scand J Immunol. 2008;68:328–36. 24. Coupland LA, Chong BH, Parish CR.Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Canser Res. 2012;72:4662-71. 25. Zaslavsky A, Baek KH,.Lynch RC et al. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood. 2010;115:4605–13. 26. Tovari J, Raso E et al. Platelet-mimicry of cancer cells: epiphenomenon with clinical significance.J.Timar. Oncology. 2005;69:185-201. 27. Muller F, Schenk W, Muller F, Mutch N, Schenk W et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139:1143-56. 28. Palumbo JS, Talmage KE, Massari JV et al. Pla-telets and fibrinogen increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105:178–85. 29. Reeves BN, Key NS. Acquired hemophilia in malignancy. Thromb Res. 2012;129:66–8. 30. Uusitalo-Jarvinen H, Kurokawa, Mueller BM et al. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2007;27:1456–62. 31. Ruf W. Tissue factor and PAR signaling in tumor progression. Thromb Res. 2007;120:7-12. 32. Sanon S, Lenihan DJ, Mouhayar E. Peripheral arte¬rial ischemic events in cancer patients.Vasc Med. 2011;16:119-30. 33. Palumbo JS, Potter JM, Kaplan LS et al. Spon-taneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. 2002;62:6966-72. 34. Stegner D, Stegner D, Nieswandt B.Platelet re-ceptor signaling in thrombus formation. J Mol Med (Berl). 2011;89:109-21. 35. Miles FL, Pruitt FL, van Golen KL et al. Stepping out of the flow: capillary extravasation in cancer me-tastasisClin Exp Metastasis. 2008;25:305-24. 36. Suzuki-Inoue K, Inoue O, Ozaki Y. Novel platelet activation receptor CLEC-2: from discovery to prospects. J. Thromb Haemost. 2011;1:44–45. 37. Thug MJ. The role of aspirin in cancer prevention.Nat Rev Clin Oncol. 2012;9:259–67. 38. Fearnley GW, Bruns AF, Wheatcroft S. et al. VEGF-A isoform-specific regulation of calcium ion flux, transcriptional activation and endothelial cell migration. Biol Open. 2015;1:87–89.




How to Cite

Desyaterik VI, Shevchenko YS. Mechanisms of hematogenous tumor metastasis. Med. perspekt. [Internet]. 2016Mar.9 [cited 2024Apr.20];21(1):10-8. Available from: